$URGN News

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target

UroGen Pharma Announces Settlement And License Agreement With Teva Pharmaceuticals Relating to JELMYTO

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript

UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder Cancer

UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution.

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45

UroGen (URGN) Q1 2026 Earnings Transcript

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma Ltd. Q1 2026 Earnings Call Summary

UroGen Pharma to Present at Upcoming Investor Conferences

Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40

Urogen Pharma Q1 Earnings Call Highlights

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate